Growth Metrics

Pacific Biosciences Of California (PACB) Free Cash Flow (2016 - 2026)

Pacific Biosciences Of California has reported Free Cash Flow over the past 16 years, most recently at -$19.9 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 38.23% year-over-year to -$19.9 million; the TTM value through Dec 2025 reached -$113.9 million, up 46.33%, while the annual FY2025 figure was -$113.9 million, 46.33% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$19.9 million at Pacific Biosciences Of California, down from -$18.6 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$17.3 million in Q2 2021 and troughed at -$98.4 million in Q1 2023.
  • A 5-year average of -$50.0 million and a median of -$45.4 million in 2025 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: crashed 273.72% in 2022 and later skyrocketed 58.32% in 2025.
  • Year by year, Free Cash Flow stood at -$34.6 million in 2021, then crashed by 89.49% to -$65.5 million in 2022, then increased by 8.99% to -$59.6 million in 2023, then skyrocketed by 45.85% to -$32.3 million in 2024, then surged by 38.23% to -$19.9 million in 2025.
  • Business Quant data shows Free Cash Flow for PACB at -$19.9 million in Q4 2025, -$18.6 million in Q3 2025, and -$29.9 million in Q2 2025.